Skip to main content
SearchLoginLogin or Signup

Reviews of "Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses"

Reviewers: Sarah Stanley, Scott Biering (UC Berkeley) | πŸ“—πŸ“—πŸ“—πŸ“— ◻️ β€’ Saumendra N. Sarkar (University of Pittsburgh) | πŸ“—πŸ“—πŸ“—πŸ“— ◻️

Published onAug 26, 2020
Reviews of "Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses"
history

You're viewing an older Release (#1) of this Pub.

  • This Release (#1) was created on Aug 26, 2020 ()
  • The latest Release (#2) was created on Nov 09, 2020 ().
key-enterThis Pub is a Review of
Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses
Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses
Description

Abstract For yet unknown reasons, severely ill COVID-19 patients often become critically ill around the time of activation of adaptive immunity. Here, we show that anti-Spike IgG from serum of severely ill COVID-19 patients induces a hyper-inflammatory response by human macrophages, which subsequently breaks pulmonary endothelial barrier integrity and induces microvascular thrombosis. The excessive inflammatory capacity of this anti-Spike IgG is related to glycosylation changes in the IgG Fc tail. Moreover, the hyper-inflammatory response induced by anti-Spike IgG can be specifically counteracted in vitro by use of the active component of fostamatinib, an FDA- and EMA-approved therapeutic small molecule inhibitor of Syk.One sentence summary Anti-Spike IgG promotes hyper-inflammation.

To read the original manuscript, click the link above. To read the reviews, click the links below.

Comments
0
comment
No comments here
Why not start the discussion?